Faculty profile

Eric Winquist

ResearcherClinical PharmacologyWestern University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Western University directory, so their courses may be missing. Find their university profile.

Eric Winquist

Researcher

Clinical Pharmacology

Health Sciences

Western University

London, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
50 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

175

Publications

1,342

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their Western University profile.

Clinical Pharmacology Drug Interactions Drug Metabolism Pharmacogenetics Pharmacogenomics

Latest papers

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).
The Journal of molecular diagnostics : JMD · 2026
The case of mistaken identity: Extraskeletal Ewing sarcoma of the prostate masquerading as small cell neuroendocrine carcinoma.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.
International journal of radiation oncology, biology, physics · 2026

All 175 publications

Latest funding

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial
CIHR · 2022 · Co-investigator
$424,575
Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians
CIHR · 2020 · Principal investigator
$1,995,001
Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study
CIHR · 2019 · Co-investigator
$1,373,176

All 4 grants and awards

From the 150 most recent of 175 publications.

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).

Bhai P, Turowec JP, Pickard LA, Haghshenas S, Karim K, McConkey H, Santos S, Kerkhof J, Black M, Breadner D, Cecchini M, Howlett C, Schenkel L, Lalonde E, Panuganty V, Raphael J, Lohmann AE, Winquist E, Lenehan J, Stewart P, Tsvetkova E, Vincent M, Fernandes R, Bauman G, Welch S, Sadikovic B

The Journal of molecular diagnostics : JMD2026

DOI: 10.1016/j.jmoldx.2025.12.007 PMID: 41654253

The case of mistaken identity: Extraskeletal Ewing sarcoma of the prostate masquerading as small cell neuroendocrine carcinoma.

Hassan A, Winquist E, Bauman G, Inman BA, Tang T

Canadian Urological Association journal = Journal de l'Association des urologues du Canada2026

DOI: 10.5489/cuaj.9626 PMID: 42531443

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.

Bahig H, Ye RZ, Aubin F, Nguyen-Tan PF, Soulieres D, Debenham BJ, Charpentier D, Palma DA, Chua N, Winquist E, Jamal R, Sultanem K, Ballivy O, Filion E, Mathew J, Maganti M, Wong P

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2026.07.052 PMID: 42586218

Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.

Fernandes R, Jabbarizadeh B, Rajeh A, Hong MMY, Baines KJ, Ernst S, Winquist E, Ali AS, Penny S, Figueredo R, Parvathy SN, Lenehan JG, Pinto DM, Silverman MS, Maleki Vareki S

Nature medicine2026

DOI: 10.1038/s41591-025-04183-8 PMID: 41606120

What Is the Impact of Treatment De-Escalation on Patient-Reported Outcomes in Patients With T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR Studies.

Dang A, Palma DA, Nichols AC, Warner A, Tran E, Bayley A, Sultanem K, Le H, Gaudet M, Karam I, Banerjee R, Tenenholz T, Winquist E, Theurer J, Goodman CD

International journal of radiation oncology, biology, physics2026

DOI: 10.1016/j.ijrobp.2026.06.3054 PMID: 42349663

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.

Zeng PYF, Meens J, Karimi AH, Pan H, Cecchini MJ, Jarycki L, Ryan SB, Dawson AE, Shaikh MH, Palma DA, Winquist E, Gunaratnam L, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC

Cell reports. Medicine2026

DOI: 10.1016/j.xcrm.2026.102820 PMID: 42143022

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Müller DC, Murtha AJ, Bacon JVW, Stephenson M, Wells C, Vasquez-Rios C, Rostin K, Rebane L, Schönlau E, Nikkola J, Alimohamed N, Basappa NS, Finch D, Ko JJ, Lavoie JM, Nappi L, Noonan K, Ong M, Ozgun G, Parimi S, Soleimani M, Sridhar SS, Toren P, Winquist E, Bernales CQ, Koudjanian M, Atwal J, Fung E, Khan L, Eigl B, Othman D, Bismar TA, Wang G, Merza R, Papadakis AI, Spatz A, Kollmannsberger C, Maurice-Dror C, Annala M, Chi KN, Vandekerkhove G, Wyatt AW, Eigl BJ

Nature communications2026

DOI: 10.1038/s41467-026-69927-7 PMID: 41760649

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR

Clinical Cancer Research202511 citationsFirst author

DOI: 10.1158/1078-0432.ccr-24-1612

Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma

De Vries-Brilland M, Hamilou Z, Ghosh S, Heng DYC, Wood LA, Basappa NS, Kollmannsberger CK, Graham J, Bhindi B, Finelli A

Oncologist20255 citations

DOI: 10.1093/oncolo/oyaf240

Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

Bou-Nehme Sawaya G, Tanguay S, Wood LA, Kollmannsberger C, Basappa NS, Bansal R, Soulières D, Finelli A, Heng DYC, Castonguay V

Clinical Genitourinary Cancer20252 citations

DOI: 10.1016/j.clgc.2025.102342

Something wrong or missing on this profile? Suggest a correction

Eric Winquist

Research

Latest papers

Latest funding

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).

The case of mistaken identity: Extraskeletal Ewing sarcoma of the prostate masquerading as small cell neuroendocrine carcinoma.

Phase 1/2 Trial of Durvalumab Plus Tremelimumab and Stereotactic Body Radiation Therapy for Metastatic Head and Neck Carcinoma.

Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.

What Is the Impact of Treatment De-Escalation on Patient-Reported Outcomes in Patients With T1-T2 Oropharyngeal Cancers? A Secondary Analysis of the ORATOR Studies.

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma

Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

PREVENT GU: Prevention of thromboembolism with rivaroxaban in GU cancer patients receiving chemotherapy: A Randomized Placebo-Controlled, Double-Blind Clinical Trial

Integrated Precision Medicine Technology and Approach for Optimal Drug Therapy for Canadians

Metabolomics for prediction of cisplatin mediated acute kidney injury: a Canadian multi-centre adult and pediatric study

CIHR Training Grant in Cancer Research and Technology Transfer (CaRTT)

Frequent collaborators

George Rodrigues

Sebastien Hotte

Keith Kwan

Christina Canil

Bret Wehrli

Aly-Khan Lalani

Julie Theurer

Piotr Czaykowski

Eitan Prisman

Jeff Chen

Houda Bahig

Nicholas Power

Antonio Finelli

Stephen Welch

Urban Emmenegger

Sisira Sarma

Shereen Ezzat

James Koropatnick

Glenn Bauman

Matthew Cecchini

Michael Ong

Janet Martin

Libni Eapen

Yun-Hee Choi

Muriel Brackstone

Som Mukherjee

Antoine Eskander

James Wright

Geoffrey Liu

Lucia Nappi

Lesley Seymour

Ramy Saleh

Alice Dragomir

Marc Gaudet

Danny Enepekides

Christopher Howlett

Laurie Ailles

Katherine Zukotynski

Olfat Kamel Hasan

Doug Coyle